generic drugs

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.

The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.

Journalist Katherine Eban says most of the generic medicine being sold in the U.S. is manufactured overseas — sometimes under questionable quality control standards. Her new book is Bottle of Lies.

Civica Rx has plans to become an alternative source of generic drugs at reasonable prices for hospitals. The company's first medicines will be the antibiotics vancomycin and daptomycin.

A new lawsuit brought by 44 states and Puerto Rico alleges an "industrywide" conspiracy by generic drug manufacturers to collude on prices and divide up the market.

A new book investigates the history of unsafe and deceptive practices by some generic drug manufacturers, and explains why U.S. regulators struggle to keep up with a global industry.

The Indianapolis-based drugmaker said Monday that it would offer a generic version of Humalog insulin, one of its best-selling medicines. The move could help blunt criticism about high prices.

Republican Orrin Hatch is leaving the Senate after 42 years. He led bipartisan efforts to get health care for more kids and AIDS patients. He also thrived on donations from the drug industry.

Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.

A consortium of hospital systems and three foundations is moving ahead with a nonprofit drugmaker that would produce some of the generic medicines health care facilities need the most.

Some health plans are refusing to count the copayment assistance offered by drugmakers as part of a patient's deductible. That means some patients are paying thousands of dollars more out-of-pocket.

Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer. Now administration officials are criticizing practices they say hold generics back.